Anti-CD3 × Anti-EGFR Bispecific-armed T Cells (EGFR BATs) therapy

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameAnti-CD3 × Anti-EGFR Bispecific-armed T Cells (EGFR BATs) therapy

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsT cell surface glycoprotein CD3 modulatorsT lymphocyte replacements

TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3

Therapy Area/IndicationsPancreatic NeoplasmsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Virginia

China Registration ClassN/A

Develop Information

Active CompaniesNavifus Co University Of Virginia

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A